南微医学
(688029)
| 流通市值：157.04亿 | | | 总市值：157.04亿 |
| 流通股本：1.88亿 | | | 总股本：1.88亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,380,540,402.29 | 1,565,377,051.9 | 699,156,940.3 | 2,755,434,907.16 |
| 营业收入 | 2,380,540,402.29 | 1,565,377,051.9 | 699,156,940.3 | 2,755,434,907.16 |
| 二、营业总成本 | 1,755,895,594.02 | 1,114,540,760.78 | 501,585,822.52 | 2,064,317,241.62 |
| 营业成本 | 843,910,468.13 | 549,527,942.42 | 239,887,378.33 | 891,287,564.51 |
| 税金及附加 | 27,825,795.78 | 18,527,184.2 | 8,649,611.75 | 33,256,403.48 |
| 销售费用 | 519,284,587.78 | 337,540,256.86 | 149,159,764.01 | 646,301,355.07 |
| 管理费用 | 303,282,452.87 | 198,621,595.69 | 97,383,711.02 | 368,831,423.56 |
| 研发费用 | 133,829,765.81 | 88,282,277.32 | 38,058,328.95 | 174,369,113.18 |
| 财务费用 | -72,237,476.35 | -77,958,495.71 | -31,552,971.54 | -49,728,618.18 |
| 其中:利息费用 | 2,735,631.47 | 1,319,238.83 | 819,271.92 | 3,314,203.53 |
| 其中:利息收入 | 48,460,748.96 | 32,619,921.79 | 14,228,994.46 | 72,032,930.77 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 464,937.53 | 403,050.42 | -7,595.89 | -472,933.8 |
| 加:投资收益 | 10,014,502.83 | 6,222,947.56 | 3,567,616.18 | 20,504,100.32 |
| 资产处置收益 | 86,844.44 | -7,425.13 | 32,402.17 | 722,720.64 |
| 资产减值损失(新) | -14,868,324.93 | -9,266,509.45 | -4,077,077.94 | -56,873,239.97 |
| 信用减值损失(新) | -1,204,435.8 | -1,177,033.94 | -1,424,241.01 | -5,541,279.32 |
| 其他收益 | 7,171,881.93 | 3,820,872.91 | 2,276,694.32 | 9,954,779.68 |
| 四、营业利润 | 626,310,214.27 | 450,832,193.49 | 197,938,915.61 | 659,411,813.09 |
| 加:营业外收入 | 627,686.97 | 333,547.2 | 125,262.08 | 1,063,989.52 |
| 减:营业外支出 | 310,654.23 | 1,445,032.67 | 274,671.75 | 702,448.35 |
| 五、利润总额 | 626,627,247.01 | 449,720,708.02 | 197,789,505.94 | 659,773,354.26 |
| 减:所得税费用 | 96,536,905.89 | 69,961,821.98 | 30,627,234.93 | 91,696,122.23 |
| 六、净利润 | 530,090,341.12 | 379,758,886.04 | 167,162,271.01 | 568,077,232.03 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 530,090,341.12 | 379,758,886.04 | 167,162,271.01 | 568,077,232.03 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 509,263,960.74 | 363,379,408.08 | 160,936,939.7 | 553,226,633.36 |
| 少数股东损益 | 20,826,380.38 | 16,379,477.96 | 6,225,331.31 | 14,850,598.67 |
| 扣除非经常损益后的净利润 | 507,807,960.6 | 363,770,923.22 | 161,073,893.72 | 544,079,798.69 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 2.72 | 1.94 | 0.86 | 2.95 |
| (二)稀释每股收益 | 2.72 | 1.94 | 0.86 | 2.95 |
| 八、其他综合收益 | 29,811,229.06 | 32,508,841.47 | 9,159,697.47 | 1,494,630.66 |
| 归属于母公司股东的其他综合收益 | 24,041,064.39 | 26,433,717.23 | 6,603,994.48 | 1,497,191.74 |
| 九、综合收益总额 | 559,901,570.18 | 412,267,727.51 | 176,321,968.48 | 569,571,862.69 |
| 归属于母公司股东的综合收益总额 | 533,305,025.13 | 389,813,125.31 | 167,540,934.18 | 554,723,825.1 |
| 归属于少数股东的综合收益总额 | 26,596,545.05 | 22,454,602.2 | 8,781,034.3 | 14,848,037.59 |
| 公告日期 | 2025-10-28 | 2025-08-12 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |